Assessment of N-Acetylcysteinein for treatment of premenstrual dysphoric disorder

Efficacy of N-Acetylcysteine for treatment of premenstrual dysphoric disorder in 18-45 year-old women in comparison with fluoxetine and placebo: A double blind randomized placebo controlled clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180604039970N1

Enrollment

120

Registered

2018-11-07

Start date

2017-05-22

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual dysphoric disorder. Premenstrual tension syndrome

Interventions

Intervention 1: Intervention group: N-acetylcystein administrators(40 persons), N-acetylcystein 900 milligrams, twice daily (N-acetylcystein powders will be derived from 200 milligrams tablet and pack

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Females with diagnosis of premenstrual dysphoric disorder based on DSM-5; aged 18-45 years

Exclusion criteria

Exclusion criteria: Lack of other mood disorders

Design outcomes

Primary

Measure	Time frame
Scores of Hamilton and Daily Record of Severity of Problems questionnaires. Timepoint: Prior to and after two periods of 2-week-treatments following 2 menstrual cycles. Method of measurement: Questionnaires of Hamilton and Daily Record of Severity of Problems.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonire Haghanifar

Esfahan University of Medical Sciences

211monaha@gmail.com+98 31 3222 2475

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026